Your browser doesn't support javascript.
loading
Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment.
Hagihara, Hideo; Shoji, Hirotaka; Hattori, Satoko; Sala, Giovanni; Takamiya, Yoshihiro; Tanaka, Mika; Ihara, Masafumi; Shibutani, Mihiro; Hatada, Izuho; Hori, Kei; Hoshino, Mikio; Nakao, Akito; Mori, Yasuo; Okabe, Shigeo; Matsushita, Masayuki; Urbach, Anja; Katayama, Yuta; Matsumoto, Akinobu; Nakayama, Keiichi I; Katori, Shota; Sato, Takuya; Iwasato, Takuji; Nakamura, Haruko; Goshima, Yoshio; Raveau, Matthieu; Tatsukawa, Tetsuya; Yamakawa, Kazuhiro; Takahashi, Noriko; Kasai, Haruo; Inazawa, Johji; Nobuhisa, Ikuo; Kagawa, Tetsushi; Taga, Tetsuya; Darwish, Mohamed; Nishizono, Hirofumi; Takao, Keizo; Sapkota, Kiran; Nakazawa, Kazutoshi; Takagi, Tsuyoshi; Fujisawa, Haruki; Sugimura, Yoshihisa; Yamanishi, Kyosuke; Rajagopal, Lakshmi; Hannah, Nanette Deneen; Meltzer, Herbert Y; Yamamoto, Tohru; Wakatsuki, Shuji; Araki, Toshiyuki; Tabuchi, Katsuhiko; Numakawa, Tadahiro.
Afiliação
  • Hagihara H; Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Japan.
  • Shoji H; Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Japan.
  • Hattori S; Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Japan.
  • Sala G; Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Japan.
  • Takamiya Y; Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Japan.
  • Tanaka M; Division of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Japan.
  • Ihara M; Department of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
  • Shibutani M; Laboratory of Genome Science, Biosignal Genome Resource Center, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
  • Hatada I; Laboratory of Genome Science, Biosignal Genome Resource Center, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan.
  • Hori K; Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Hoshino M; Department of Biochemistry and Cellular Biology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.
  • Nakao A; Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan.
  • Mori Y; Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan.
  • Okabe S; Department of Cellular Neurobiology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Matsushita M; Department of Molecular Cellular Physiology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.
  • Urbach A; Department of Neurology, Jena University Hospital, Jena, Germany.
  • Katayama Y; Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Matsumoto A; Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Nakayama KI; Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  • Katori S; Laboratory of Mammalian Neural Circuits, National Institute of Genetics, Mishima, Japan.
  • Sato T; Laboratory of Mammalian Neural Circuits, National Institute of Genetics, Mishima, Japan.
  • Iwasato T; Laboratory of Mammalian Neural Circuits, National Institute of Genetics, Mishima, Japan.
  • Nakamura H; Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Goshima Y; Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Raveau M; Laboratory for Neurogenetics, RIKEN Center for Brain Science, Wako, Japan.
  • Tatsukawa T; Laboratory for Neurogenetics, RIKEN Center for Brain Science, Wako, Japan.
  • Yamakawa K; Laboratory for Neurogenetics, RIKEN Center for Brain Science, Wako, Japan.
  • Takahashi N; Department of Neurodevelopmental Disorder Genetics, Institute of Brain Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Kasai H; Laboratory of Structural Physiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Inazawa J; Department of Physiology, Kitasato University School of Medicine, Sagamihara, Japan.
  • Nobuhisa I; Laboratory of Structural Physiology, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kagawa T; International Research Center for Neurointelligence (WPI-IRCN), UTIAS, The University of Tokyo, Tokyo, Japan.
  • Taga T; Research Core, Tokyo Medical and Dental University, Tokyo, Japan.
  • Darwish M; Department of Stem Cell Regulation, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
  • Nishizono H; Department of Stem Cell Regulation, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
  • Takao K; Department of Stem Cell Regulation, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
  • Sapkota K; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Nakazawa K; Department of Behavioral Physiology, Graduate School of Innovative Life Science, University of Toyama, Toyama, Japan.
  • Takagi T; Medical Research Institute, Kanazawa Medical University, Kahoku, Japan.
  • Fujisawa H; Department of Behavioral Physiology, Graduate School of Innovative Life Science, University of Toyama, Toyama, Japan.
  • Sugimura Y; Department of Behavioral Physiology, Faculty of Medicine, University of Toyama, Toyama, Japan.
  • Yamanishi K; Department of Neuroscience, Southern Research, Birmingham, United States.
  • Rajagopal L; Department of Neuroscience, Southern Research, Birmingham, United States.
  • Hannah ND; Institute for Developmental Research, Aichi Developmental Disability Center, Kasugai, Japan.
  • Meltzer HY; Department of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, Toyoake, Japan.
  • Yamamoto T; Department of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, Toyoake, Japan.
  • Wakatsuki S; Department of Neuropsychiatry, Hyogo Medical University School of Medicine, Nishinomiya, Japan.
  • Araki T; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, United States.
  • Tabuchi K; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, United States.
  • Numakawa T; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, United States.
Elife ; 122024 Mar 26.
Article em En | MEDLINE | ID: mdl-38529532
ABSTRACT
Increased levels of lactate, an end-product of glycolysis, have been proposed as a potential surrogate marker for metabolic changes during neuronal excitation. These changes in lactate levels can result in decreased brain pH, which has been implicated in patients with various neuropsychiatric disorders. We previously demonstrated that such alterations are commonly observed in five mouse models of schizophrenia, bipolar disorder, and autism, suggesting a shared endophenotype among these disorders rather than mere artifacts due to medications or agonal state. However, there is still limited research on this phenomenon in animal models, leaving its generality across other disease animal models uncertain. Moreover, the association between changes in brain lactate levels and specific behavioral abnormalities remains unclear. To address these gaps, the International Brain pH Project Consortium investigated brain pH and lactate levels in 109 strains/conditions of 2294 animals with genetic and other experimental manipulations relevant to neuropsychiatric disorders. Systematic analysis revealed that decreased brain pH and increased lactate levels were common features observed in multiple models of depression, epilepsy, Alzheimer's disease, and some additional schizophrenia models. While certain autism models also exhibited decreased pH and increased lactate levels, others showed the opposite pattern, potentially reflecting subpopulations within the autism spectrum. Furthermore, utilizing large-scale behavioral test battery, a multivariate cross-validated prediction analysis demonstrated that poor working memory performance was predominantly associated with increased brain lactate levels. Importantly, this association was confirmed in an independent cohort of animal models. Collectively, these findings suggest that altered brain pH and lactate levels, which could be attributed to dysregulated excitation/inhibition balance, may serve as transdiagnostic endophenotypes of debilitating neuropsychiatric disorders characterized by cognitive impairment, irrespective of their beneficial or detrimental nature.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endofenótipos / Disfunção Cognitiva Limite: Animals / Humans Idioma: En Revista: Elife Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Endofenótipos / Disfunção Cognitiva Limite: Animals / Humans Idioma: En Revista: Elife Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão País de publicação: Reino Unido